trkain1

TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity.

ITK/TRKA-IN-1 is a chemical compound that functions as a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA). With an IC50 value of 1.0 nM, it effectively inhibits the activity of ITK, while demonstrating a remarkable 96% inhibition of TRKA.

TrkA-IN-10 (PI-15R) 是一种选择性TrkA抑制剂，其对于TrkA、TrkB和TrkC的IC50值分别为17 nM、8 nM和5 nM，用于癌症研究。

RET/TRKA-IN-1 (Compound 13) 是一种同时抑制 RET (IC50=0.375 µM) 和 TRKA 的双功能抑制剂。它对 LC-2 和 KM12 细胞的活力具有显著抑制效果，GI50 分别为 0.72 和 0.25 μM。此外，RET/TRKA-IN-1 能够在 G1 期引起细胞周期停滞。

hTrkA-IN-1 is a potent and orally active inhibitor of TrkA kinase with an IC 50 of 1.3 nM, compound 2.hTrkA-IN-1 can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al.

FLT3/TrKA-IN-1 是一种有效的 FLT3/TrKA 双激酶抑制剂，能够作用于 FLT3 (IC50: 43.8 nM)、FLT3-ITD (IC50: 97.2 nM)、FLT3-TKD (IC50: 92.5 nM) 和 TrKA (IC50: 23.6 nM)。FLT3/TrKA-IN-1 能够将细胞周期阻滞在 G0/G1 期，并诱导细胞凋亡 (apoptosis)，具有抗增殖作用。FLT3/TrKA-IN-1 具有潜力进行急性髓性白血病 (AML) 的研究。